Wet AMD

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Options facilitate increased durability for patients with retinal degeneration.

Carl Regillo, MD, takes us through the history of the port delivery system, from ideation to FDA approval.

Susvimo, previously called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.

Findings from the Archway trial showed that the PDS effect is long-lasting, consistent, and comparable to those seen with monthly injections.

Outlook Therapeutics completes Phase 3 NORSE TWO safety and efficacy trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treatment of wet AMD.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Investigators have found that 78% of neovascular AMD cases have been detected using the PHP home monitoring system.

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery, offering an alternative to more frequent anti-VEGF injections for people with wet AMD.

Investigators corroborate the hypothesis that retinal ganglion cells with dendrites stratified in the off sublaminae could be damaged.

Amid pandemic, physicians and patients have embraced remote technology.

An updated PDS procedure reduces complications.

The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.

This novel intravitreal gene therapy may also hold potential for the treatment of diabetic macular edema.

Injections and implants continue to create further positive outcomes for patients.

Novel option demonstrates stable to improved visual acuity and retinal thickness

Minimizing clinic visits, maximizing use of imaging modalities are key

Rapid fluid identification may result in better visual outcomes

Specialist explains approaches for a variety of cases encountered during procedure

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.